Global (68M) cardiomyopathies market projected to grow to $9.63bn by 2031
Pharmaceutical Technology
DECEMBER 15, 2022
Based on the previous 7MM report, growth in the cardiomyopathies market was primarily attributed to the market release of Bristol Myers Squibb’s Camzyos (mavacamten) and the upcoming launch of Cytokinetics’ aficamten, both of which are myosin inhibitors indicated for the management of obstructive hypertrophic cardiomyopathy (HCM).
52 
Let's personalize your content